AKT1 and breast cancer: Mutations in the RAS/RAF/MEK/ERK pathway are not as common in breast cancer; however, overactivation of this pathway is common [132], which could be due to extensive crosstalk with PI3K/AKT (Figure 5) and other major signaling pathways.